Talus Bio

Talus Bio

Biotechnology Research

Seattle, WA 3,430 followers

Gene regulator profiling in live cells for drug development

About us

Talus Bioscience is a venture-backed early-stage biotechnology startup company working on drug development for gene regulators. Talus Bio spun out of two leading institutions in September 2020 (University of Washington and Altius Institute for Biomedical Sciences) and is located in Seattle, WA. We are building a data-enabled drug development platform that will focus primarily on small-molecule drug development in oncology. Talus Bio's platform measures a drug’s ability to disrupt a gene regulator within its natural, non-engineered cellular environment. Furthermore, a single experiment using the platform measures activity for about 1,000 gene regulators simultaneously, providing information on in-cell drug activity and specificity in a single experiment. To accomplish this, we combine innovative cell processing with high-sensitivity quantitative proteomics and advanced downstream analytics. As a company, Talus Bio focuses on two parallel efforts to prove that our technology can open up the world of gene regulation for drug discovery: - Developing internal programs against previously undruggable gene regulators in cancers with poor standard of care - Partnering with pharma, biotech, and academic labs to help progress their pipeline of gene regulator drugs

Website
http://talus.bio
Industry
Biotechnology Research
Company size
11-50 employees
Headquarters
Seattle, WA
Type
Privately Held
Founded
2020

Locations

Employees at Talus Bio

Updates

  • View organization page for Talus Bio, graphic

    3,430 followers

    Congratulations to Talus Bio co-founder and CTO, Lindsay Pino! The Human Proteome Organization honored Lindsay with the 2024 HUPO Rising Star Award. The award recognizes her contributions to the field of proteomics, from her research excellence and entrepreneurial spirit, to her educational and community-building efforts that have helped propel the field to the next wave of discovery. At Talus Bio, Lindsay is the driving force behind our MARMOT platform that leverages functional proteomics, automated biology, and machine learning to discover first-in-class treatments for cancer and diseases caused by transcription factor dysregulation. Join us in celebrating her accomplishments and this well-deserved recognition!

    • No alternative text description for this image
  • View organization page for Talus Bio, graphic

    3,430 followers

    Thanks to Talus Bio board member, Omri Amirav-Drory from NFX, for this insightful blog post that clearly articulates the rationale behind the parallel business models of developing a platform and developing assets, because "great platforms should make great assets". We couldn't agree more!

    View profile for Omri Amirav-Drory, graphic

    General Partner at NFX

    My answer to the platform vs asset debate in techbio: Great platforms build great assets. But, you have to be strategic. It's about balance. You can advance a lead asset, while leveraging your platform (services, targets, other assets) to gain revenue + grow your platform. If you do it right, you create a cycle of growth. Our advice on striking this balance: https://lnkd.in/gVRxU7SU Quick examples below: Most companies fall somewhere on a continuum between monetizing the platform itself vs using assets to fuel platform development. Example: Twist Bioscience. They monetized a DNA synthesis platform and became a huge company. They pivoted toward assets later. But most bioplatforms aren't like that. Most need to pursue assets earlier to fuel development and show traction. Example: Mammoth Biosciences owns key IP in small CRISPR systems and has monetized various aspects of that IP through pharma deals. These partnerships boosted their credibility and funded future R&D. Now, they have strong pharma ties and millions in non-dilutive funding for internal development. My most recent essay tackles striking this balance, and what you need to show by Series A to be on the right track.

    Why Great Bioplatforms Will Always Win

    Why Great Bioplatforms Will Always Win

    nfx.com

  • View organization page for Talus Bio, graphic

    3,430 followers

    We're proud of Lindsay Pino's willingness to volunteer her time and expertise within the Skyline community! This is a great example of one of the many ways that Talus Bio's leadership team is giving back to fellow proteomics scientists.

    View profile for Lindsay Pino, graphic

    Co-Founder and CTO at Talus Bio (YC S21) - nothing is undruggable - unlocking transcription factors with functional proteomics and genomics

    Final day of Skyline Online Session 3, "Advanced Proteomics Topics", done! ✅ Big thanks to this session's instructors: Ariana Shannon, Juan Camilo Rojas Echeverri, Evan Hubbard, Alessio Di Ianni. Not only did they do a great job fielding questions from across the entire Skyline ecosystem, but also some really tough questions about sample preps, assay development, and experimental design. #TeamMassSpec #proteomics

    • No alternative text description for this image
  • View organization page for Talus Bio, graphic

    3,430 followers

    Congratulations to our new Head of Biology, Gaelle Mercenne, for being featured in STAT's’ “Up & Down the Ladder.” We learned so much about her, for example, if she were a piece of lab equipment she’d be a plate shaker: "I want to know what is possible and what is not possible when considering drug targets, especially transcription factors. What is druggable? I love using new techniques to identify small molecules that inhibit previously considered undruggable targets. So the idea of being something to shake things up and challenging concepts and questions, it’s who I am.” At Talus Bio, we’ve got a lot of movers n’ shakers on the team–but only one Gaelle. Read the whole conversation with our newest team member in ed silverman's latest column, linked in comments (subscription required).

    • No alternative text description for this image
  • Talus Bio reposted this

    View profile for Brian Glaister, graphic

    Director of Product - Head of New Business Incubation @ Axon | Start-up investor and mentor | Working to help solve society's biggest problems through technology & entrepreneurship

    Enjoying a Friday evening with Ti Zhao, Ivan Liachko 🇺🇦, Lindsay Pino, and Matthew Bick at the Pack Ventures annual meeting learning about how AI is transforming drug discovery and genomics. We've all been enjoying the recent GenAI wave which is, in part, possible by the huge amount of information that is readily available on the internet to train models. Intetestingly, As Lindsay noted, there are tons of data out there to support drug discovery, but it is not necessarily easy to access and even further, most of the data is about what DOESN'T work so you have to work hard to tell the models what success looks like. We are just starting to scratch the surface at harnessing AI to treat deadly diseases. Pack is a pre-seed and seed-focused venture fund, uniquely positioned within the University of Washington network to support UW spinouts and companies founded by UW alumni. A big part of what I love about being an L.P. in Pack is getting to support some of the smartest founders on the planet and learn about how they are literally taking the fiction out of science fiction. And you can too! Ken Horenstein and Ti are actively raising Fund II and are committed to building a diverse pool of accredited investors, not just those that fall into the ultra high net worth category. If you'd like to explore joining the Pack, let me know and I'd be happy to connect you to learn more.. #venturecapital #startups #innovation #Entrepreneurship #ai #artificialintelligence

    • No alternative text description for this image
  • View organization page for Talus Bio, graphic

    3,430 followers

    We’re proud to welcome Gaelle Mercenne, PhD to the Talus Bio team as our new Head of Biology. A true pioneer at the forefront of AI-accelerated drug discovery, Gaelle will leverage our MARMOT platform to identify novel targets and optimize transcription factor modulators. “Bringing Gaelle aboard allows us to accelerate new molecules from hits identified by the MARMOT platform to fully optimized, first-in-class drugs to address diseases driven by transcription factor dysregulation.” – Talus Bio co-founder & CEO, Alex Federation, PhD Gaelle brings the deep expertise necessary to expand our pipeline of transcription factor therapeutics for cancer, inflammatory, cardiometabolic, and rare diseases. Prior to joining the team, she was a pivotal early hire at Recursion Pharmaceuticals before serving as Associate Director of Research Innovation at Sumitomo Pharma America. Follow the links in this post's comments section to learn more about Gaelle and Talus Bio’s mission to accelerate drug development for the most challenging therapeutic targets.

    • No alternative text description for this image
  • View organization page for Talus Bio, graphic

    3,430 followers

    Take an inside look at Talus Bio with our COO/CFO Michelle Briscoe, “This company is based on the people and the scientists. They are the ones that—every day—are coming in with these new creative ideas of how to achieve these goals, this mission: which is getting new drugs to patients that previously didn’t have therapeutic options.” Tune in to the Life Science Success Podcast for the full conversation with Don Davis PhD, MBA and hear how the Talus Bio team stays thriving and empowered to achieve their mission-critical work. 🔊 https://lnkd.in/dpTN6BDf

    • No alternative text description for this image
  • View organization page for Talus Bio, graphic

    3,430 followers

    Talus Bio has hired two amazing scientists who were previously venture analysts in this WRF program, Daniele Canzani, PhD and Lillian Tatka, PhD. This unique experience offered them invaluable insights into the business landscape of startups and biotech companies, further strengthening our team. 

    View profile for William Canestaro, PhD, graphic

    Healthcare and Biotech Investor | Advisor | Executive | Board Member

    The best part of working at the Washington Research Foundation is the opportunity to work with our amazing venture analysts. Here are some facts about the program: Over the past 5 years, we've had 24 amazing analysts and we are about to welcome our next 5 analysts this year! They help us with diligence on grants and investments and are a critical part of operations. They've gone on to some amazing places after leaving the program: Flagship Pioneering, Propel Bio Partners, Brass Tacks Health, Arzeda, Talus Bio, and Lumen Bioscience among others! Despite the success of the program, we've never had a reunion until last week when we were able to gather current and former analysts together. Keep an eye on this group, they'll be the future of Seattle biotech and engineering! Parker Sommerville, PhD Cade Ellis Ito Sam Berry, Ph.D. Emily Rabe Heidi Weakly, PhD Kevin P. Jiang Daniele Canzani, PhD Miranda Lyons-Cohen, PhD Bhargav Vemuri Lillian Tatka, PhD Vanessa Nguyen, PhD Sophia Jannetty Louisa Helms Ashish Phal Issa Benna, PhD Alex Pollock

    • No alternative text description for this image

Similar pages

Browse jobs

Funding

Talus Bio 10 total rounds

Last Round

Seed

US$ 11.2M

See more info on crunchbase